Biopharma News

Mar 19, 2018
By BioPharm International Editors
Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.
Mar 19, 2018
By BioPharm International Editors
The companies intend to jointly develop and commercialize Lenvima (lenvatinib mesylate) as a monotherapy and an in-combination therapy for treating multiple cancer types.
Mar 13, 2018
By BioPharm International Editors
The $11.6-billion acquisition strengthens Sanofi's position in hematology and specialty medicines.
Mar 09, 2018
By BioPharm International Editors
The European Medicines Agency has called for the immediate suspension and recall of AbbVie and Biogen's multiple sclerosis drug Zinbryta (daclizumab beta).
Mar 08, 2018
By BioPharm International Editors
Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.
Mar 06, 2018
By BioPharm International Editors
The pharma major will spin out six molecules in early stage inflammation and autoimmune programs into a new company called Viela Bio.
Feb 28, 2018
By BioPharm International Editors
A jury verdict requiring Gilead Sciences to pay $2.54 billion for patent infringement to competitor Merck & Co. over Gilead's Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir), two best-selling hepatitis C drugs, has been overturned.
Feb 28, 2018
By BioPharm International Editors
Merck & Co. has acquired oncology-focused biopharmaceutical company Viralytics to strengthen Merck's oncology pipeline.
Feb 27, 2018
By BioPharm International Editors
Roche will acquire oncology-focused healthcare technology and services company Flatiron Health for $1.9 billion to further its personalized oncological healthcare strategy.
Feb 21, 2018
By BioPharm International Editors
The companies have partnered to develop and commercialize vectorized antibodies against tau for Alzheimer's and other neurodegenerative diseases.
native1_300x100
lorem ipsum